No profile data available.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) is a healthcare company in the allergy treatment pharmaceuticals industry, based in Huzhou, China, with about 1,808 full-time employees.
It reported revenue of 1.06 billion CNY for fiscal year 2025, up 14.8% from fiscal year 2024, and net income of 380.94 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 252.84 million CNY, up 10.7% from a year before. Its market capitalization was 10.47 billion CNY as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit.
Zhejiang Wolwo Bio-Pharmaceutical reported 1.06 billion CNY in revenue for fiscal year 2025, up 14.8% from 925.39 million CNY in fiscal year 2024. In Q1 2026 revenue was 252.84 million CNY.
10.47 billion CNY as of October 9, 2026.